Sorry, your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Proof

PSMA+mCRPC ad campaign for Pluvicto. Image of a man standing in front of body parts with targeting rings

Targeted therapy goes nuclear

Combining state of the art PSMA testing with a targeted radioligand, AAA (Novartis) introduced LOCAMETZ and PLUVICTO for metastatic castration-resistant prostate cancer in 2022.

Targeted therapy goes nuclear

Powered by Syneos Health

Locations